Introduction
Recent studies have implicated centrosome amplification in the origin of chromosomal instability during tumor development. Theodor Boveri first suggested this notion nearly a century ago (Boveri, 1914) . While the role of centrosome amplification in the origin of malignant tumors remains a controversial issue, several emerging lines of evidence suggest that cell cycle pathways converge on the centrosome and implicate this organelle in the control of cell cycle progression in addition to its function as a microtubule organizing center. Here we review the relationship between cell cycle regulation and centrosome amplification in the development of cancer.
The centrosome influences cell structure through the nucleation and organization of cytoplasmic microtubules (Kirschner and Mitchison, 1986) . Interphase cells contain a single centrosome that is typically located near the nucleus and contains of a pair of centrioles that anchor the recruitment of pericentriolar material including the microtubule nucleating protein g-tubulin (Bobinnec et al., 1998) . Centrioles are small organelles (*200 nm diameter and 400 nm in length) consisting of a cylindrical array of nine triplet microtubules (Dutcher, 2001a,b) .
The centrosome is duplicated once, and only once, during a normal cell cycle to give rise to two centrosomes that function as the spindle poles of the dividing cell (Kellogg, 1989) . This process is most clearly illustrated by duplication of the centrioles themselves. In early G1 phase of the cell cycle the two centrioles are typically oriented in a characteristic orthogonal arrangement. As cells pass the G1 restriction point and commit to DNA replication and subsequent cell division, the two centrioles separate a short distance from one another and nascent procentrioles form at the proximal end and orthogonal to each pre-existing centriole (Adams and Kilmartin, 2000; Wheatley, 1982) . During G2/M phase centrosome duplication is completed and each new centrosome (i.e. mitotic spindle pole) contains one old and one new centriole. The presence of only two centrosomes in the cell as it enters mitosis ensures the equal segregation of sister chromatids to each daughter cell. Mitotic spindle poles also play a role in determining the position and orientation of the cleavage furrow and in exit from cytokinesis (Khodjakov and Rieder, 2001; Piel et al., 2001) .
Control of centrosome duplication during cell cycle progression
In addition to their role as the microtubule organizing center in interphase and mitotic cells, centrosomes have also been suggested to play a role in regulation of cell cycle progression itself, since microsurgical removal or laser ablation of centrioles results in failure of cytokinesis and in G1 arrest (Hinchcliffe et al., 2001; Khodjakov and Rieder, 2001 ). Centrosome duplication is strictly co-ordinated with DNA replication, mitosis and cell division (Sluder and Hinchcliffe, 2000) . The key stages of cell cycle progression are governed by the subcellular location, and periodic activation and subsequent inactivation of the serine/threonine cyclindependent protein kinases (Cdks) (Pines, 1999) . Evidence suggesting a direct role for the Cdks in regulating the mitotic activity of centrosomes first came to light from studies on the localization of cyclin B and Cdk1 (p34 cdc2 ) at the centrosome during G2/M phase, and from experiments using Xenopus cell free extracts that implicated cyclin A and B in the control of microtubule dynamics (Bailly et al., 1992; Debec and Montmory, 1992; Verde et al., 1990 Verde et al., , 1992 . More recently, the direct involvement of Cdk2 activity in regulation of centrosome duplication was established (Hinchcliffe and Sluder, 2002) . Treatment of CHO cells with an inhibitor of G1 phase progression, mimosine, also arrested centrosome duplication. Centrosome duplication was initiated when cells were allowed to pass the restriction point and commit to completing the remaining phases of the cell cycle (Matsumoto et al., 1999) . In cycling cells, multiple rounds of centrosome duplication occurred when DNA replication was inhibited using hydroxyurea (HU) treatment, thus demonstrating that the centrosome cycle is not strictly dependent on DNA replication per se (Balczon et al., 1995) . Nonetheless, both centrosome duplication and DNA replication are dependent on Cdk2 activation and are blocked by the Cdk2 inhibitors butyrolactone I or roscovitine (Keezer and Gilbert, 2002; Matsumoto et al., 1999) . Cdk2/cyclin E activity was subsequently identified as a key regulator of the centrosome cycle, since centrosome duplication was blocked by the small protein inhibitors of Cdk2, p21/waf1 or p27, or by immuno-depletion of Cdk2 or cyclin E, and centrosome duplication was restored by excess purified Cdk2/ cyclin E (Hinchcliffe et al., 1999; Lacey et al., 1999; Matsumoto et al., 1999) . Importantly, separation of the centriole pair, an early event in the centrosome duplication cycle, was shown to be dependent on Cdk2/cyclin E activity, suggesting that a Cdk-mediated phosphorylation event regulates centriole pair cohesion (Lacey et al., 1999) . Nucleophosmin is a likely target of Cdk2/cyclinE in this process (Okuda, 2002) . This protein associates specifically with unduplicated centrosomes in early G1 phase of the cell cycle and dissociates from centrosomes upon its phosphorylation by Cdk2/cyclin E during S and G2 phases. Microinjection of Swiss 3T3 fibroblasts with anti-nucleophosmin antibody blocked nucleophosmin phosphorylation and suppressed the onset of centrosome duplication . Expression of a nucleophosmin dominantnegative mutant, which cannot be phosphorylated by Cdk2/cyclinE, also blocked centrosome duplication (Tokuyama et al., 2001) . Interestingly, nucleophosmin is also phosphorylated by the mitotic kinases Cdk1/ cyclin B and Cdk2/cyclin A. While the functional significance of mitotic phase nucleophosmin phosphorylation is presently unresolved, the sequential activation of Cdks and subsequent phosphorylation of nucleophosmin has been suggested to signal both the dissociation of nucleophosmin from the centrosome at S and G2 phase, and their re-association at mitosis (Peter et al., 1990; Tokuyama et al., 2001) . Finally, centrosome duplication also depends on the phosphorylation status of retinoblastoma tumor suppressor Rb, which governs the availability of the E2F transcription factor to promote S phase progression (Meraldi et al., 1999) . Taken together, these findings establish the mechanism by which DNA replication and centrosome duplication are coordinated during the cell cycle ( Figure 1 ). Both DNA replication and centrosome duplication are controlled by the Rb pathway, both processes depend on downstream transcriptional consequences of E2F activity, and both processes require Cdk2/cyclin activation.
Additional protein phosphorylation events play key roles in controlling centrosome behavior and function during the cell cycle (Fry et al., 2000b) . Centrosome protein phosphorylation increases dramatically at the onset of mitosis and falls precipitously at the metaphase/anaphase transition (Lutz et al., 2001; Rao et al., 1989; Vandre and Borisy, 1989; Vandre et al., 2000) (Figure 1 ). In addition to the Cdks, several protein kinases and protein phosphatases have been identified that localize at centrosomes and affect the phosphorylation status of centrosome targets (Table 1) .
Importantly, several centrosome-associated kinases and target substrates implicated in the regulation of the centrosome duplication cycle become altered during the development of centrosome amplification in cancer. For example, centrosome amplification and chromosomal instability seen in malignant tumors can result from over-expression of the breast tumor amplified kinase BTAK/STK15, and inappropriate phosphorylation of centrosome proteins serves as a sensitive marker for centrosome amplification in tumor tissue (Katayama et al., 2001; Lingle et al., 1998; Miyoshi et al., 2001; Zhou et al., 1998; Dutertre et al., 2002) . In addition, other important players in cancer development, such as the tumor suppressor proteins p53, and BRCA-1 and -2, also reside at the centrosome, albeit only transiently (Giannakakou et al., 2000; Hsu and White, 1998; Pockwinse et al., 1997; Xu et al., 1999) . The presence of such a large group of key regulators of cell cycle progression at the centrosome has led to speculation that the centrosome itself may provide an important structural context for coordinating cell cycle regulation (Doxsey, 2001; Fry et al., 2000b; Sluder and Hinchcliffe, 1998) . Figure 1 Phosphoepitope-specific antibodies have been particularly useful in analysis of phosphoproteins during the centrosome cycle. This figure illustrates the phosphorylation of the centrosome protein centrin during the cell cycle as revealed using a phosphocentrin-specific antibody (Lutz et al., 2001) . Centrin is located at the centrosome throughout the cell cycle and is phosphorylated at the G2/M transition, remains phosphorylated during prophase and metaphase, and is dephosphorylated at the onset of anaphase and consequently by early interphase of the next cell cycle no phosphocentrin remains Centrosome amplification and disregulation of cell cycle checkpoints G1/S and G2/M checkpoints are surveillance mechanisms that enforce dependency on the orderly completion of cell cycle events (Hartwell and Weinert, 1989) . When activated, these checkpoints inhibit the formation and/or activation of Cdks and thereby induce cell cycle arrest (Murray, 1992) . Several key proteins involved in checkpoint control also physically associate with centrosomes and/or appear to play an important role in centrosome homeostasis (Brown et al., 1994; Giannakakou et al., 2000; Hsu and White, 1998; Morris et al., 2000; Pockwinse et al., 1997; Xu et al., 1999) . The tumor suppressor p53 controls both G1/ S and G2/M checkpoints and its inactivation also leads to disregulation of the centrosome cycle (Tarapore and Fukasawa, 2002) . In human cancers, p53 mutation correlated with occurrence of centrosome amplification in carcinomas of the breast, head and neck, and prostate, and in neuroectodermal tumors (Carroll et al., 1999; Ouyang et al., 2001; Weber et al., 1998) . In some cases tumors that retained wild-type p53 also showed amplified centrosomes. Many of these tumors also showed overexpression of Mdm2 that inactivates p53 by promoting its degradation (Carroll et al., 1999) . In experimental studies, loss of p53 by gene targeting and gain-of-function p53 mutations resulted in disregulation of centrosome duplication leading to the generation of functionally amplified centrosomes and aberrant mitoses (Fukasawa et al., 1996; Murphy and Rosen, 2000; Tarapore et al., 2001b) . Interestingly, p53 mutations associated with cyclin E overexpression synergistically increased the frequency of centrosome amplification in cultured cells, and in tumors derived from p53-null, heterozygous, and wild-type mice (Mussman et al., 2000) . These findings suggest that an imbalance between negative and positive cell cycle regulators could accelerate centrosome defects ( Figure  2) . p53 is involved in the control of centrosome duplication through its transcriptional regulation of several downstream targets including the Cdk inhibitor p21/waf1 (el-Deiry et al., 1993; Harper et al., 1993) . As discussed earlier, p21/waf1 blocks centrosome duplication through inhibition of Cdk2/cyclin E activity. Moreover, reduced activity of p21/waf1 by antisense expression in human cell lines resulted in endoreduplication and centrosome amplification (Mantel et al., 1999) . Nonetheless, while introduction of wild-type p53 into p53 7/7 mouse embryonic fibroblasts re-established centrosome homeostasis, overexpression of p21/ waf1 only partially restored control of centrosome duplication in p53-null fibroblasts (Tarapore et al., Figure 2 Centrosome amplification in the development of cancer may originate through inactivation of G1/S and/or G2/M cell cycle checkpoints (red lightning bolts). Inactivation of these checkpoints could lead to centriole over-duplication, through acceleration of G1/S phase progression and/or defects in cytokinesis. One consequence of centrosome amplification is the development of multipolar mitotic spindles and aneuploidy 2001a). GADD45, another downstream product of the p53 pathway, has been implicated in both DNA damage repair and activation of the G2/M checkpoint (Kastan et al., 1992; Wang et al., 1999) . This checkpoint is abrogated in cells lacking GADD45 expression leading to centrosome amplification, mitotic spindle defects, and consequent unequal chromosomal segregation Hollander and Fornace, 2002) .
Centrosome amplification and genomic instability can develop independently of loss of p53 function, suggesting the presence of alternative mechanisms leading to disregulation of centrosome homeostasis (Donehower et al., 1992; Eshleman et al., 1998; Lengauer et al., 1997; Lingle et al., 2002) . The high risk human papillomavirus (HPV) types 16 and 18 each carry two viral oncogenes, E6 and E7, which have been implicated in the induction of centrosome amplification in human cell lines (Duensing, 2001; Duensing et al., 2000 Duensing et al., , 2001a . HPV E6 and E7 may interfere with centrosome homeostasis by targeting different pathways. Whereas E6 may operate through inactivation of p53 function, E7 may lead to centrosome amplification through inactivation of the Rb and G1/S checkpoint disregulation (Duensing and Munger, 2002) .
Mutations in the BRCA1 and BRCA2 tumor suppressor genes associated with the development of familial breast and ovarian cancers also have been implicated in the loss of checkpoint control of the centrosome cycle (Deng, 2002) . The BRCA1 protein localizes at the centrosome during mitosis and the hypophosphorylated form of BRCA1 coimmunoprecipitates with g-tubulin, a centrosomal component essential for nucleation of microtubules (Hsu and White, 1998; Maul et al., 1998; Xu et al., 1999) . Mouse embryo fibroblasts carrying gene targeted deletions in BRCA1 or BRCA2 showed a defective G2/M checkpoint function, amplified centrosomes, aberrant mitoses and aneuploidy (Tutt et al., 1999; Xu et al., 1999) . Taken together, these studies show that centrosome amplification can develop through dysfunction of alternative pathways that converge on G1/S and G2/M checkpoint regulators.
Centrosome amplification in cancer
Recent studies implicate centrosome amplification in the pathogenesis of cancer (Gustafson et al., 2000; Kuo et al., 2000; Lingle et al., 1998; Pihan et al., 1998; Sato et al., 1999; Weber et al., 1998) . The term 'centrosome amplification' is commonly used to signify centrosomes that appear significantly larger than normal; as defined by the staining of structural centrosome components in excess of that seen in the corresponding normal tissue or cell type, centrosomes that contain more than four centrioles, and/or when more than two centrosomes are present within a cell (Figure 3 ). In addition, amplified centrosomes also show protein hyperphosphorylation and altered functional properties such as an increased microtubule nucleating capacity (Lingle et al., 1998; Meraldi et al., 2002; Miyoshi et al., 2001; Salisbury et al., 1999; Zhou et al., 1998) . Electron microscope images revealed supernumerary centrioles in centrosomes of humans and animal model tumors, including leiomyosarcoma, neuroblastoma, glioma and thymic carcinoid tumors (Friedlander, 1982; Kaneko et al., 1980; Seifert, 1978; Sharp et al., 1981 Sharp et al., , 1982 Ring, 1982) . Subsequent systematic analyses of centrosomes in human breast carcinomas and a mouse model for prostate cancer revealed a range of abnormalities in centrosome structure including: excess number of centrioles, increased pericentriolar material, abnormal centriole orientation, and inverted polarity of centrosome location (i.e., with the centrosome located within the cell in a basal rather than an apical position relative to the nucleus) Schatten et al., 2000) . These structural centrosome abnormalities have been implicated as a potential cause of loss of cell and tissue architecture seen in cancer (i.e. anaplasia) through altered centrosome function in Figure 3 Normal (a) and tumor (b) colon tissues from the same patient were stained with antibodies against cytokeratin 20 (red), to identify epithelial cells, pericentrin (green), to label centrosomes, and with Hoechst 33342, to label nuclei. Normal crypt epithelial cells (a) contain a single apical centrosome and basal nucleus. The aneuploid tumor (b) has amplified centrosomes that are larger and more numerous than those in the normal tissue. Fluorescence signal from centrosomes from these same sections is illustrated (a' and b'). Centrosome amplification may be the cause of the chromosomal instability present in this tumor microtubule nucleation and organization, and resulting in chromosome missegregation during mitosis as a consequence of multipolar spindle formation.
Correlation of centrosome amplification, aneuploidy and chromosomal instability
What is the evidence that centrosome defects play a direct role in the origin of tumor phenotypes? A key issue in this regard is whether or not centrosome amplification leads to chromosomal instability and aneuploidy or is a consequence of them; the proverbial chicken and egg conundrum. Aneuploidy, a form of genomic instability characterized by gains and losses of whole chromosomes, occurs early in the development of many tumor types, suggesting that it may play a role in both tumorigenesis and tumor progression. Indeed, aneuploidy is present in the great majority of malignant tumors, in contrast to benign tumors, which are most often diploid. Aneuploidy may lead to phenotypic heterogeneity in cancer, reflecting the persistent generation of new chromosomal variations (Mitelman, 1994) . This persistent generation of chromosomal variations was later defined as 'chromosomal instability' (CIN) and can be thought of as a rate of change in karyotype (Lengauer et al., 1997) . Boveri first recognized these features of cancer cells nearly a century ago and proposed that centrosome defects could lead to mitotic and subsequent chromosomal abnormalities (Boveri, 1914) . These concepts have been resurrected in recent investigations on the possible role of centrosome amplification in the development of aneuploidy through unequal chromosome segregation due to multipolar mitotic spindles.
Centrosome amplification and chromosomal instability occur exclusively in aneuploid tumors and tumorderived cell lines in contrast to diploid tumors, which contain centrosomes that are functionally and structurally normal (Ghadimi et al., 2000; Lingle et al., 1998 Lingle et al., , 2002 . The degree of genomic instability parallels the degree of centrosome abnormalities in cell lines from breast , pancreas , prostate (Pihan et al., 2001) , colon (Ghadimi et al., 2000) , and cervix tumors (Skyldberg et al., 2001) , from short-term culture of mouse mammary tumors (Montagna et al., 2002) , and from SV40 ST overexpressing fibroblasts (Gaillard et al., 2001) . Centrosome abnormalities were higher in high-grade prostate tumors (Pihan et al., 2001 ) and high-grade cervical tumors (Skyldberg et al., 2001) than in low-grade tumors. Centrosome amplification and chromosomal instability can be induced by over-expression of the centrosomal protein pericentrin and by over-expression of the centrosome kinase BTAK/STK15, suggesting that alternative mechanisms may lead to centrosome defects and consequent genomic instability (Pihan et al., 2001; Zhou et al., 1998) . In prostate cancer, centrosome amplification has been implicated in the development of abnormal mitoses and CIN facilitating progression to advanced stages of the disease (Ouyang et al., 2001; Pihan et al., 2001; Schatten et al., 2000) . Strong support for a direct mechanistic link between centrosome amplification and CIN is suggested by the significant linear correlation between centrosome amplification and the rate of change in karyotype (CIN) seen in human breast tumors . Although such correlation alone does not necessarily imply cause and effect, these observations have led many authors to propose the hypothesis that centrosome amplification is the primary cause of genomic instability observed in most tumors (Gaillard et al., 2001; Lingle et al., 2002; Sato et al., 2001; Skyldberg et al., 2001 ). An alternative hypothesis has been proposed that chromosomal instability seen in cancer cells is caused by aneuploidy, that is that aneuploidy itself destabilizes the karyotype and thus initiates CIN leading to widespread heterogeneity in tumor cell phenotypes (Duesberg, 1999; Duesberg and Rasnick, 2000; Duesberg et al., 1998; Li et al., 2000) .
Several independent lines of evidence support the proposition that centrosome abnormalities drive genomic instability. In a recent study of human breast tumors, all specimens of ductal carcinoma in situ examined showed significant centrosome amplification, while aneuploidy is present, on average, in only 35% of in situ breast tumors, suggesting that centrosome amplification is an early event that occurs prior to invasion in breast tumors . Furthermore, cells transfected to express the HPV E7 oncoprotein undergo centrosome amplification prior to developing nuclear morphology associated with aneuploidy (Duensing et al., 2000 (Duensing et al., , 2001b . And finally, in a xenograft model of pancreatic cancer, metastatic foci showed a higher incidence of centrosome amplification than did the primary xenograft, and abnormal centrosome numbers were accompanied by a higher frequency of abnormal mitoses (Shono et al., 2001) . Taken together, these studies suggest that not only does centrosome amplification drive CIN, but also that this instability causes the tumor to progress to a more advanced stage.
Centrosome amplification as potential indicator of tumor aggressiveness
Can centrosome amplification be utilized as an indicator of tumor progression and the potential to develop aggressive tumor phenotypes? Centrosome amplification is not only characteristic of tumors in general, but also is more pronounced in advanced stage malignancies, in recurrent tumors, and in cell lines that show more aggressive malignant phenotypes in xenograph animal models Gustafson et al., 2000; Kuo et al., 2000; Miyoshi et al., 2001 ). These observations suggest that centrosome amplification might be useful in monitoring tumor progression and phenotypic diversity in cancer. Finally, in association with other established prognostic factors, centrosome amplification may be helpful in predicting outcomes and survival of patients with cancer.
